per lonning

per lonning

University of Bergen, Norway
Verified email at helse-bergen.no
Cited by 67521
Breast Cancer Endocrine therapy chemoresistance germline risk factors
Tian-Li Wang

Tian-Li Wang

Professor of Pathology, Oncology, and Gynecology/Obstetrics, Johns Hopkins University
Verified email at jhmi.edu
Cited by 36735
Cancer genomics Epigenomics Notch signaling Chemoresistance
Sendurai A. Mani

Sendurai A. Mani

Associate Director for Translational Oncology, Legorreta Cancer Center at Brown University
Verified email at brown.edu
Cited by 33257
cancer biology metastasis cancer stem cells EMT chemoresistance
Jose J. G. Marin

Jose JG Marin

University of Salamanca, Dept. Physiology and Pharmacology, HEVEPHARM, IBSAL …
Verified email at usal.es
Cited by 18357
Hepatology Pathophysiology Pharmacology Chemoresistance
Anna-mart Engelbrecht

Anna-mart Engelbrecht

Stellenbosch University
Verified email at sun.ac.za
Cited by 16835
breast cancer chemoresistance tumor microenvironment
Manfred Ogris

Manfred Ogris

Professor for Pharmaceutical Sciences, University of Vienna
Verified email at univie.ac.at
Cited by 15357
Cancer gene therapy chemoresistance molecular imaging
Francisco Vega MD PhD

Francisco Vega MD PhD

MD Anderson Cancer Center
Verified email at mdanderson.org
Cited by 10539
Hematopathology lymphoma chemoresistance Smoothened diffuse large B cell lymphoma
Rocio IR Macias

Rocio IR Macias

University of Salamanca
Verified email at usal.es
Cited by 10430
Hepatology Chemoresistance Drug targeting Liver cancer
August Vidal i Bel

August Vidal i Bel

Hospital Universitari de Bellvitge-IDIBELL
Verified email at bellvitgehospital.cat
Cited by 9343
Pathology gynecologic cancer chemoresistance animal models orthoxenografts
A. Emre Sayan

A. Emre Sayan

Assoc. Prof. in cancer cell biology, University of Southampton
Verified email at soton.ac.uk
Cited by 9296
Cancer biology metastasis apoptosis chemoresistance epithelial mesenchymal transition
1 - 10